Close

Citi Cuts Dendreon (DNDN) Price Target to $10 Amid 'Significant Threats to Provenge'

April 12, 2012 9:52 AM EDT
Get Alerts DNDN Hot Sheet
Price: $0.13 --0%

Rating Summary:
    2 Buy, 15 Hold, 9 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 0 | Down: 0 | New: 0
Join SI Premium – FREE
Shares of Dendreon (Nasdaq: DNDN) are moving higher Thursday morning despite some concerning comments and a reduced price target from Citi's Yaron Werber.

The analyst now sees Dendreon shares rising to $10 over the next year, down from a previous target of $14. Werber sees "significant threats to Provenge" from Johnson & Johnson's (NYSE: JNJ) Zytiga and Medivation's (Nasdaq: MDVN) MDV3100. He said oral drugs may prove to offer a longer overall survival benefit, in addition to being cheaper.

Werber is currently modeling for J&J's Zytiga to be approved for pre-chemo patients in 2013. The analyst expects Medivation's product to be cleared in 2014.

The Citi analyst maintains a Neutral rating on Dendreon shares.

With the stock last trading up 0.5 percent to $9.48, Citi's new target implies potential upside of about 5 percent.

Visit our Analyst Ratings page to track all the market-moving analyst action on shares of Dendreon.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst PT Change

Related Entities

Citi